OTLK (STOCKS)
Outlook Therapeutics, Inc. Common Stock
$0.260000
+0.011000 (+4.42%)
Prev close: $0.249000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Robert Charles Jahr
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $26.66M
- Employees
- 23
- P/E (TTM)
- -0.23
- P/B (TTM)
- -0.43
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
5
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q1)
|
$-0.22 | $-0.18 | -0.0364 | -19.83% |
|
Sep 2025 (Q4)
|
$-0.19 | $-0.26 | +0.0684 | +26.47% |
|
Jun 2025 (Q3)
|
$-0.55 | $-0.40 | -0.1488 | -37.09% |
|
Mar 2025 (Q2)
|
$-0.40 | $-0.61 | +0.2100 | +34.43% |
Financial Statements
| Revenues | $157.57K |
| Benefits Costs and Expenses | $104.57M |
| Costs And Expenses | $95.00M |
| Operating Expenses | $57.74M |
| Selling, General, and Administrative Expenses | $36.60M |
| Depreciation and Amortization | $118.33K |
| Research and Development | $21.15M |
| Operating Income/Loss | -$58.94M |
| Income/Loss Before Equity Method Investments | -$104.27M |
| Income/Loss From Continuing Operations After Tax | -$102.86M |
| Income/Loss From Continuing Operations Before Tax | -$104.41M |
| Income/Loss From Equity Method Investments | -$146.35K |
| Interest Income/Expense Operating, Net | -$332.01K |
| Net Income/Loss | -$102.86M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$102.86M |
| Net Income/Loss Available To Common Stockholders, Basic | -$102.86M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.62 |
| Diluted Earnings Per Share | -$2.62 |
| Basic Average Shares | 132,168,145 |
| Diluted Average Shares | 132,168,145 |
| Assets | $18.24M |
| Current Assets | $17.17M |
| Inventory | $3.46M |
| Other Current Assets | $13.71M |
| Noncurrent Assets | $1.07M |
| Liabilities | $56.79M |
| Current Liabilities | $49.06M |
| Accounts Payable | $7.32M |
| Wages | $1.55M |
| Other Current Liabilities | $40.18M |
| Noncurrent Liabilities | $7.73M |
| Equity | -$38.55M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$38.55M |
| Liabilities And Equity | $18.24M |
| Net Cash Flow From Operating Activities | -$55.80M |
| Net Cash Flow From Operating Activities, Continuing | -$55.80M |
| Net Cash Flow From Investing Activities | -$2.97M |
| Net Cash Flow From Investing Activities, Continuing | -$2.97M |
| Net Cash Flow From Financing Activities | $58.78M |
| Net Cash Flow From Financing Activities, Continuing | $58.78M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$102.86M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$102.86M |
| Other Comprehensive Income/Loss | $0.00 |